论文部分内容阅读
目的:观察和评价益脾养肝方联合TACE和3DCRT治疗原发性肝癌的临床疗效。方法:51例原发性肝癌患者随机分为治疗组(26例),给予中药益脾养肝方联合TACE及3DCRT治疗;对照组(25例),给予TACE和3DCRT治疗。两组疗程35~42 d(根据3DCRT治疗时间而变化)。观察和比较两组病例在治疗前后中医证候、实体瘤大小、细胞免疫功能、肝功能、生存率等方面的相关指标并进行统计分析。结果:经治疗后,治疗组中医疗效总有效率88.0%,对照组中医疗效总有效率32.0%,两组比较有显著性差异(P<0.05)。治疗组在中医证候改善,CD3+、CD3+CD4+变化,降低ALT、AST等方面优于对照组,差异有统计学意义(P<0.05)。治疗组在实体瘤大小改变、生存率等方面均优于对照组,但差异无统计学意义(P>0.05﹚。结论:益脾养肝方联合TACE和3DCRT治疗原发性肝癌,可以明显改善患者临床症状、改善生化指标、提高患者生活质量,且安全可靠。
Objective: To observe and evaluate the clinical efficacy of Yipi Yanggan Decoction combined with TACE and 3DCRT in the treatment of primary liver cancer. Methods: Fifty-one patients with primary liver cancer were randomly divided into treatment group (n = 26) treated with TGP and 3DCRT, and control group (n = 25) treated with TACE and 3DCRT. Two courses of treatment 35 ~ 42 d (according to 3DCRT treatment time changes). Observed and compared two groups of patients before and after treatment of TCM syndromes, solid tumor size, cellular immune function, liver function, survival and other aspects of the relevant indicators and statistical analysis. Results: After treatment, the total effective rate of TCM in treatment group was 88.0%, while that in control group was 32.0%. There was significant difference between the two groups (P <0.05). The treatment group was better than the control group in TCM syndrome improvement, CD3 +, CD3 + CD4 +, ALT, AST reduction, the difference was statistically significant (P <0.05). The treatment group was better than the control group in the size of the solid tumor, survival rate and other aspects, but the difference was not statistically significant (P> 0.05). Conclusion: YBP combined with TACE and 3DCRT can significantly improve the clinical symptoms, improve the biochemical indexes, improve the quality of life of patients and be safe and reliable.